评论"在稳定的非传染性儿科尿道炎中减少和取消Adalimumab剂量:一项开放标签,前性试点研究"
Karthikeyan Kandaswamy1, Ajay Guru1
1Department of Cariology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.
Ocular immunology and inflammation
|August 15, 2024
概括
这项试点研究探讨了在患有稳定非传染性脑膜炎的儿童中减少或停止阿达利穆马布 (ADA) 的作用. 研究结果表明,有可能优化治疗,但需要进一步的研究.
科学领域:
- 眼科医生 眼科 眼科
- 儿科风湿病学 儿科风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 非传染性儿科卵膜炎需要长期管理.
- 阿达利穆马布 (ADA) 是治疗儿科紫外炎的有效生物疗法.
- 通过减少或取消药物来优化ADA治疗是可取的,以尽量减少暴露和潜在的副作用.
研究的目的:
- 评估在患有稳定非传染性脑膜炎的儿童中降低和取消阿达利穆马布 (ADA) 剂量的可行性和初步疗效.
- 评估通过减少ADA暴露来维持疾病控制的潜力.
- 收集试点数据用于未来,更强大的研究设计.
主要方法:
- 一个开放的标签,未来的试点研究设计.
- 包括患有稳定非传染性脑膜炎的儿科患者在阿达利穆马布治疗中.
- 实施标准化方案,用于降低剂量和取消阿达利姆巴的使用.
主要成果:
- 关于减少剂量和戒断策略结果的初步数据.
- 在逐渐缩减和退出阶段评估疾病控制和安全性.
- 确定与成功降低或取消剂量相关的因素.
结论:
- 在某些患有稳定非传染性脑膜炎的儿科患者中,降低和取消阿达利穆马布的剂量可能是可行的.
- 通过随机对照试验进行进一步的调查是有必要的,以证实这些发现.
- 对于未来的研究,建议进行方法改进,包括更大的样本规模和更长的随访时间.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
103
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
103
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K
Renal Failure: Dose Adjustments
71
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
71
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124


